Abstract title | Presenter / Lead author | Presentation details |
|---|
INVESTIGATOR-INITIATED STUDIES |
Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single-arm, prospective phase II trial (RIFLE) | Chen Yajie, Zhang Zhen, Fudan University Shanghai Cancer Center, Shanghai, China | #e15570 Publication Only: Gastrointestinal Cancer—Colorectal and Anal |
A propensity score matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: real-world data | Lina He, Shuiping Tu, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China | #e15564 Publication Only: Gastrointestinal Cancer—Colorectal and Anal |
Phase Ib/II trial of hepatic arterial infusion chemotherapy (HAIC) in combination with fruquintinib as third-line therapy for refractory unresectable colorectal cancer liver metastases | Zhu Xu, Peking University Cancer Hospital and Institute, Beijing, China | #3561 Poster Session - Gastrointestinal Cancer—Colorectal and Anal |
Efficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study | Jianjun Peng, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China | #3536 Poster Session - Gastrointestinal Cancer — Colorectal and Anal |
A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic arteryinfusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival | Lu Wang, Zhang Ti, Fudan University Shanghai Cancer Center, Shanghai, China | #3543 Poster Session - Gastrointestinal Cancer — Colorectal and Anal |
Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial | Suxia Luo, Fei Ma, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China | #e16021 Publication Only: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary |
Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): a multicenter, single-arm, open-label, phase II study | Tao Zhang, Zhenyu Lin, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | TPS3643 Poster Session: Gastrointestinal Cancer — Colorectal and Anal |
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study | Junjie Peng, Wenhua Li, Fudan University Shanghai Cancer Center, Shanghai, China | #3567 Poster Session: Gastrointestinal Cancer — Colorectal and Anal |
Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: updated results of a multicenter, single-arm, phase 2 trial | Yongshun Chen, Wensi Zhao, Renmin Hospital of Wuhan University, Wuhan, China | #3571 Poster Session: Gastrointestinal Cancer — Colorectal and Anal |
Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort | Fuxiang Zhou, Wenbo Wang, Zhongnan Hospital of Wuhan University, Wuhan, China | #3591 Poster Session: Gastrointestinal Cancer —Colorectal and Anal |
Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multi-centered retrospective study | Lu Xie, Binghao Li, Peking University People’s Hospital, Beijing, China; The Second Affiliated Hospital Zhejiang University, Hangzhou, China | #11528 Poster Session: Sarcoma |
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study | Hui Xu, Zhongnan Hospital of Wuhan University. Wuhan, China | #e15003 Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology |
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): an open-Label, single-Arm, phase II Study | Dongsheng Zhang, Sun Yat-sen University Cancer Center, Guangzhou, China | #e16297 Publication Only: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary |
Surufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non-small cell lung cancer (NSCLC) | Yanfang Zheng, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China | #e20543 Publication Only: Lung Cancer — Non-Small Cell Metastatic |